Polaris Capital Management LLC Purchases 13,300 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Polaris Capital Management LLC boosted its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 29.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 58,300 shares of the company’s stock after acquiring an additional 13,300 shares during the quarter. Polaris Capital Management LLC’s holdings in Harmony Biosciences were worth $2,006,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in HRMY. Pacer Advisors Inc. raised its holdings in shares of Harmony Biosciences by 18.2% during the 4th quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company’s stock worth $78,452,000 after buying an additional 351,582 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in Harmony Biosciences by 27.1% during the third quarter. Massachusetts Financial Services Co. MA now owns 660,391 shares of the company’s stock worth $26,416,000 after acquiring an additional 140,690 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Harmony Biosciences by 68.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 230,428 shares of the company’s stock valued at $9,217,000 after purchasing an additional 93,622 shares in the last quarter. Citigroup Inc. increased its position in Harmony Biosciences by 9.8% during the 3rd quarter. Citigroup Inc. now owns 177,843 shares of the company’s stock worth $7,114,000 after purchasing an additional 15,859 shares in the last quarter. Finally, HealthInvest Partners AB grew its stake in shares of Harmony Biosciences by 335.2% during the third quarter. HealthInvest Partners AB now owns 151,875 shares of the company’s stock worth $6,075,000 after buying an additional 116,975 shares during the last quarter. 86.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

HRMY has been the subject of several recent research reports. Cantor Fitzgerald upped their price objective on Harmony Biosciences from $51.00 to $58.00 and gave the company an “overweight” rating in a research note on Wednesday, October 30th. Needham & Company LLC restated a “buy” rating and issued a $52.00 price objective on shares of Harmony Biosciences in a report on Monday, January 13th. Oppenheimer reaffirmed an “outperform” rating and set a $59.00 target price (up from $56.00) on shares of Harmony Biosciences in a report on Wednesday, October 30th. Finally, HC Wainwright reissued a “buy” rating and issued a $75.00 price target on shares of Harmony Biosciences in a research note on Monday, January 27th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $55.00.

Insider Transactions at Harmony Biosciences

In related news, insider Jeffrey Dierks sold 1,123 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $40.00, for a total transaction of $44,920.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Jeffrey M. Dayno sold 19,293 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $40.13, for a total transaction of $774,228.09. The disclosure for this sale can be found here. Insiders sold a total of 72,452 shares of company stock worth $2,831,679 in the last quarter. Insiders own 30.80% of the company’s stock.

Harmony Biosciences Price Performance

HRMY opened at $37.99 on Tuesday. The firm has a market cap of $2.17 billion, a P/E ratio of 18.00, a PEG ratio of 0.51 and a beta of 0.80. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $28.14 and a fifty-two week high of $41.61. The firm has a 50-day moving average of $35.77 and a 200 day moving average of $35.50.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.